| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0002-9149(99)00698-0 |
| P698 | PubMed publication ID | 10568656 |
| P2093 | author name string | Kodama I | |
| Kamiya K | |||
| Toyama J | |||
| P2860 | cites work | The effect of amiodarone, a new anti-anginal drug, on cardiac muscle | Q24669966 |
| Amiodarone: biochemical evidence for binding to a receptor for class I drugs associated with the rat cardiac sodium channel | Q28342765 | ||
| Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction | Q33970406 | ||
| Differential and tissue-specific regulation of the multiple rat c-erbA messenger RNA species by thyroid hormone | Q34239775 | ||
| Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction | Q34415281 | ||
| Effects of Amiodarone and Bepridil on Ventricular Depolarization and Repolarizationa | Q35227028 | ||
| Resting, and rate-dependent depression of Vmax of guinea-pig ventricular action potentials by amiodarone and desethylamiodarone | Q35754950 | ||
| Effects of long-term oral administration of amiodarone on the electromechanical performance of rabbit ventricular muscle | Q35871237 | ||
| Comparison of the chronic and acute effects of amiodarone on the calcium and potassium currents in rabbit isolated cardiac myocytes | Q35873960 | ||
| Does amiodarone affect heart rate by inhibiting the intracellular generation of triiodothyronine from thyroxine? | Q36004441 | ||
| Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents | Q36434545 | ||
| The historical development, cellular electrophysiology and pharmacology of amiodarone | Q38596609 | ||
| Effect of oral triiodothyronine during amiodarone treatment for ventricular premature complexes | Q39541478 | ||
| Amiodarone: Historical development and pharmacologic profile | Q40156963 | ||
| Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects | Q40172905 | ||
| Amiodarone and post-MI patients | Q40488579 | ||
| Controlling cardiac arrhythmias by lengthening repolarization: historical overview | Q40779074 | ||
| Cellular electropharmacology of amiodarone | Q40888033 | ||
| Expanding indications for the use of Class III agents in patients at high risk for sudden death | Q40938926 | ||
| Antiarrhythmic drug therapy for ventricular arrhythmias: current perspectives | Q41112408 | ||
| Voltage- and use-dependent modulation of calcium channel current in guinea pig ventricular cells by amiodarone and des-oxo-amiodarone | Q41139598 | ||
| Acute and chronic effects of amiodarone on mammalian ventricular cells | Q41279579 | ||
| Effects of class III antiarrhythmic drugs on the Na(+)-activated K+ channels in guinea-pig ventricular cells | Q42232591 | ||
| Desethylamiodarone is a competitive inhibitor of the binding of thyroid hormone to the thyroid hormone α1-receptor protein | Q42276695 | ||
| Desethylamiodarone is a noncompetitive inhibitor of the binding of thyroid hormone to the thyroid hormone beta 1-receptor protein | Q42285062 | ||
| Block of cardiac sodium channels by amiodarone studied by using Vmax of action potential in single ventricular myocytes | Q42561319 | ||
| The effects of amiodarone on the electrocardiogram of the guinea-pig are not explained by interaction with thyroid hormone metabolism alone | Q42573076 | ||
| Block of single cardiac Na+ channels by antiarrhythmic drugs: the effect of amiodarone, propafenone and diprafenone | Q43683887 | ||
| Differential Effects of Amiodarone and Desethylamiodarone on Calcium Antagonist Receptors | Q44436917 | ||
| Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone | Q46159179 | ||
| Amiodarone alters thyroxine transfer and distribution in humans | Q46201174 | ||
| Use-dependent effects of amiodarone on Vmax in cardiac Purkinje and ventricular muscle fibers | Q46294164 | ||
| Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone | Q46989385 | ||
| Amiodarone and thyroid hormone action | Q48512947 | ||
| Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. | Q51536095 | ||
| Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. | Q51592904 | ||
| Amiodarone is a dose-dependent noncompetitive and competitive inhibitor of T3 binding to thyroid hormone receptor subtype beta 1, whereas disopyramide, lignocaine, propafenone, metoprolol, dl-sotalol, and verapamil have no inhibitory effect. | Q51598836 | ||
| Amiodarone blocks inactivated cardiac sodium channels | Q53929101 | ||
| Evidences of antagonism between amiodarone and triiodothyronine on the K+ channel activities of cultured rat cardiomyocytes. | Q54205483 | ||
| Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. | Q55054117 | ||
| In vivo effects of amiodarone on cardiac beta-adrenoceptor density and heart rate require thyroid hormones | Q67541590 | ||
| Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. A meta-analysis | Q67903871 | ||
| An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985 | Q68024944 | ||
| Electrophysiologic effects of desethylamiodarone, an active metabolite of amiodarone: comparison with amiodarone during chronic administration in rabbits | Q68263566 | ||
| Two types of sodium channel block by class-I antiarrhythmic drugs studied by using Vmax of action potential in single ventricular myocytes | Q68455521 | ||
| Amiodarone | Q68930408 | ||
| Effects of amiodarone and its metabolite, desethylamiodarone, on the electrophysiologic properties of isolated cardiac muscle | Q68955965 | ||
| Interaction of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors | Q68964233 | ||
| The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction | Q69012466 | ||
| Frequency-dependent effects of amiodarone on atrioventricular nodal function and slow-channel action potentials: evidence for calcium channel-blocking activity | Q69122924 | ||
| Electropharmacology of amiodarone: absence of relationship to serum, myocardial, and cardiac sarcolemmal membrane drug concentrations | Q69653883 | ||
| Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite | Q69688204 | ||
| Rate-related electrophysiologic effects of long-term administration of amiodarone on canine ventricular myocardium in vivo | Q69962160 | ||
| Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy | Q70367697 | ||
| Decreased transport of thyroxine (T4), 3,3',5-triiodothyronine (T3) and 3,3',5'-triiodothyronine (rT3) into rat hepatocytes in primary culture due to a decrease of cellular ATP content and various drugs | Q70370199 | ||
| Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy | Q70446958 | ||
| Amiodarone inhibits the conversion of thyroxine to triiodothyronine in isolated rat hepatocytes | Q70616975 | ||
| Electrophysiologic effects of amiodarone: experimental and clinical observation relative to serum and tissue drug concentrations | Q70635769 | ||
| Contemporary clinical trials in ventricular tachycardia and fibrillation: implications of ESVEM, CASCADE, and CASH for clinical management | Q70864697 | ||
| Antagonism between T3 and amiodarone on the contractility and the density of beta-adrenoceptors of chicken cardiac myocytes | Q71989452 | ||
| SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs | Q72242665 | ||
| Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death | Q73914750 | ||
| Vesnarinone prolongs action potential duration without reverse frequency dependence in rabbit ventricular muscle by blocking the delayed rectifier K+ current | Q73937003 | ||
| P433 | issue | 9A | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | amiodarone | Q410061 |
| P304 | page(s) | 20R-28R | |
| P577 | publication date | 1999-11-01 | |
| P1433 | published in | American Journal of Cardiology | Q2208417 |
| P1476 | title | Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent | |
| P478 | volume | 84 |
| Q30985909 | A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data. |
| Q34871558 | A benefit-risk assessment of class III antiarrhythmic agents |
| Q36333201 | A general mechanism for drug promiscuity: Studies with amiodarone and other antiarrhythmics |
| Q42949803 | Acute amiodarone promotes drift and early termination of spiral wave re-entry. |
| Q53902453 | Amiodarone inhibits cardiac ATP-sensitive potassium channels. |
| Q34722445 | Amiodarone sensitizes human glioma cells but not astrocytes to TRAIL-induced apoptosis via CHOP-mediated DR5 upregulation |
| Q35048107 | Amiodarone: an emergency medicine perspective. |
| Q64908100 | Analgesic effects of amiodarone in mouse models of pain. |
| Q43952443 | Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation |
| Q37151751 | Anticonvulsant and hypnotic effects of amiodarone |
| Q44445840 | Antifungal Activity of Amiodarone Is Mediated by Disruption of Calcium Homeostasis |
| Q37590158 | Atrial fibrillation: mechanisms, therapeutics, and future directions |
| Q37093085 | Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. |
| Q37584282 | Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation |
| Q40426127 | Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. |
| Q37494653 | Atrial-selective sodium channel block for the treatment of atrial fibrillation. |
| Q31886054 | Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of Torsade de Pointes arrhythmias |
| Q35210010 | Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk. |
| Q49603813 | Cholesterol and desmosterol dancing to the beat of a different drug |
| Q43622845 | Comparison of digoxin versus low-dose amiodarone for ventricular rate control in patients with chronic atrial fibrillation |
| Q34571023 | Drugs, their targets and the nature and number of drug targets |
| Q46966624 | Effect of atrial electrical remodeling on the efficacy of antiarrhythmic drugs: comparison of amiodarone with I(Kr)- and I(to)/IKur-blockade in vivo. |
| Q33807062 | Effect of dronedarone on Na+, Ca2+ and HCN channels |
| Q42147329 | Effect of intravenous amiodarone on QT and T peak-T end dispersions in patients with nonischemic heart failure treated with cardiac resynchronization-defibrillator therapy and electrical storm |
| Q33776456 | Effects of amiodarone on short QT syndrome variant 3 in human ventricles: a simulation study. |
| Q24601144 | Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves |
| Q35892164 | Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. |
| Q28367852 | Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone |
| Q37728831 | Electrophysiological mechanisms of sophocarpine as a potential antiarrhythmic agent |
| Q37847174 | Emerging antiarrhythmic agents: a personal view from the Far East |
| Q42798412 | Generation of confluent cardiomyocyte monolayers derived from embryonic stem cells in suspension: a cell source for new therapies and screening strategies |
| Q59356716 | In Vitro and In Vivo Activity of Amiodarone Against Ebola Virus |
| Q92669207 | In silico study of the effects of anti-arrhythmic drug treatment on sinoatrial node function for patients with atrial fibrillation |
| Q51017616 | In-silico assessment of the dynamic effects of amiodarone and dronedarone on human atrial patho-electrophysiology. |
| Q40471512 | Inhibition of cellular responses to insulin in a rat liver cell line. A role for PKC in insulin resistance. |
| Q41810063 | Inhibitory effect of amiodarone on Na(+)/Ca(2+) exchange current in guinea-pig cardiac myocytes |
| Q43900869 | Intravenous amiodarone modifies autonomic balance and increases baroreflex sensitivity in conscious rats |
| Q100946026 | Low dose amiodarone reduces tumor growth and angiogenesis |
| Q34308117 | Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias |
| Q44473263 | Multiple cellular electrophysiological effects of azimilide in canine cardiac preparations |
| Q47927776 | Neuroprotective effects of amiodarone in a mouse model of ischemic stroke. |
| Q38751315 | Novel ion channel targets in atrial fibrillation. |
| Q44066866 | Opposite effects of iv amiodarone on cardiovascular vagal and sympathetic efferent activities in rats |
| Q82321776 | Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects |
| Q44372485 | Pharmacological cardioversion of recent onset atrial fibrillation with intravenous amiodarone in patients receiving long-term amiodarone therapy: is it reasonable? |
| Q36662909 | Pharmacotherapy considerations in advanced cardiac life support |
| Q37315220 | Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations |
| Q38226807 | Pulmonary Vein Sleeves as a Pharmacologic Model for the Study of Atrial Fibrillation |
| Q38241316 | Ranolazine as a promising treatment option for atrial fibrillation: electrophysiologic mechanisms, experimental evidence, and clinical implications |
| Q36534150 | Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation. |
| Q38268013 | SEURAT-1 liver gold reference compounds: a mechanism-based review |
| Q38103541 | Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update |
| Q28476186 | Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling |
| Q46155820 | Shortening of the electromechanical window in the ketamine/xylazine-anesthetized guinea pig model to assess pro-arrhythmic risk in early drug development |
| Q45055479 | Surface atrial frequency analysis in patients with atrial fibrillation: a tool for evaluating the effects of intervention |
| Q33665436 | Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria |
| Q46291533 | Synthesis and 2D-QSAR Study of Active Benzofuran-Based Vasodilators. |
| Q42958865 | Synthesis and preliminary evaluation of the antimicrobial activity of selected 3-benzofurancarboxylic acid derivatives. |
| Q64251177 | Synthesis of New Derivatives of Benzofuran as Potential Anticancer Agents |
| Q33716230 | The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism |
| Q39175155 | The class III anti-arrhythmic agent, amiodarone, inhibits voltage-dependent K(+) channels in rabbit coronary arterial smooth muscle cells. |
| Q36548317 | The effect of amiodarone pretreatment on survival of mice with cocaine toxicity |
| Q79987911 | The influence of hyperlipoproteinemia on in vitro distribution of amiodarone and desethylamiodarone in human and rat plasma |
| Q43446655 | The protective effect of amiodarone in lung tissue of cecal ligation and puncture-induced septic rats: a perspective from inflammatory cytokine release and oxidative stress |
| Q36342116 | The virtual heart as a platform for screening drug cardiotoxicity |
| Q27001737 | Towards a better understanding of QT interval variability |
| Q49053130 | Turbulent electrical activity at sharp-edged inexcitable obstacles in a model for human cardiac tissue |
| Q40574936 | Zebrafish as a model for cardiovascular development and disease |
Search more.